

**Amendments to the Specification**


On November 17, 2003, Applicants filed a Preliminary Amendment in which they amended the first page of the application to add a section cross-referencing related applications. This section appeared immediately after the title on page 1. Please further amend this paragraph to read as follows:

**Cross Reference to Related Applications**

The present application is a continuation of U.S. 09/631,116, filed on August 2, 2000 (now U.S. Patent 6,680,321), which is a continuation of U.S. 08/836,830, filed on April 27 24, 1997 (now U.S. Patent 6,130,222). The '830 application represents U.S. national phase of PCT/SE96/01635, with an international filing date of December 11, 1996 and which was published in English under Article 21(2) of the PCT on July 3, 1997. The international application claims priority to Swedish application no. 9504661-1, filed on December 22, 1995.

Please amend the abstract that appears on page 105 of the application to read as follows:

Compounds of the formula (I)



(I)

as well as their pharmaceutically acceptable salts, and pharmaceutical compositions ~~comprising~~ comprise the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.